Definium Therapeutics
722 posts
Definium Therapeutics
@definiumtx
Definium Therapeutics (formerly MindMed) is a biotech company forging a new era of psychiatry by applying precision to psychedelic medicine.
- MindMed and the entire field of psychedelic medicine are ready to take off! #removethestigma #mentalhealthawareness
- We are excited to start our human clinical trial with DMT - the active ingredient in Ayahuasca. forbes.com/sites/natanpon…
- Massive news for the world of psychedelic medicine and its potential benefits.
- A new study finds that patients who take a single psychedelic dose of psilocybin, 25mg, in conjunction with therapy report rapid and significant reduction in depression symptoms. bit.ly/3EupYDG
- It's time to profoundly change how we address mental health. 🧠
- “Psychedelic therapeutics have moved from the fringes of medicine to the mainstream.” 🍄
- The FDA has cleared MindMed’s IND application for MM-120, our proprietary, pharmacologically optimized form of LSD. Our Phase 2b dose-optimization trial of MM-120 for the treatment of Generalized Anxiety Disorder is expected to start in early 2022. mindmed.co/news/press-rel…
- For the first time in history, Mental Health had its own agenda item at this year’s World Health Assembly.
- "A 2020 study from Johns Hopkins University showed that two doses of psilocybin produced rapid and large reductions in depressive symptoms, with most participants showing improvement and half of the study participants achieving full remission." bit.ly/3ajuQ14
- Research has shown that the hallucinogenic compound psilocybin in mushrooms may have long-lasting benefits in reducing anxiety and depression.
- Happy Birthday to the mind behind MindMed, our CEO and Co-Founder, @thejrrahn! 🚀
- Research has shown that psychedelics can help treat historically difficult-to-treat conditions by essentially “reshaping” the way “parts of the brain talk to each other.” Companies like MindMed are helping pave the way.
